RPSE Res.Phm.Reg S

    RNS Number : 2381C
  Research Pharmaceutical SRV, Inc
  28 August 2008
   

    August 28, 2008


    ReSearch Pharmaceutical Services, Inc.
    Continued Trading on AIM

    ReSearch Pharmaceutical Services, Inc. ("RPS" or the "Company"), a leading provider of integrated clinical development outsourcing
solutions to the bio-pharmaceutical industry, announces that its common stock will continue to trade on AIM beyond September 1, 2008. 
Previously the Company had announced that it would cancel trading of its common stock on AIM on September 1, 2008.

    As a United States based company, the Company believes that a listing in the United States would, over time, increase the liquidity of
its common stock and improve its potential access to United States based investors.  The Company has received approval from its stockholders
at its Annual Meeting to cancel its common stock from trading on AIM in anticipation of becoming listed in the United States.

    In accordance with this authority, the Company reserves the right to cancel its common stock from trading on AIM at any time on or prior
to December 31, 2008, subject to the Company publicly announcing the date of cancellation at least 10 business days prior to the intended
date of cancellation of the common stock.  Absent such announcement, the Company's common stock and warrants will remain admitted to trading
on AIM.

    As previously disclosed, if the common stock's admission to trading on AIM is cancelled, the Company's nominated adviser has indicated
that it will resign and therefore trading of the warrants will be suspended and, if within one month the Company has not appointed another
nominated adviser, the admission of the warrants to trading on AIM will also be cancelled. The Company currently does not intend to appoint
a new nominated advisor if the common stock are cancelled from trading.

    The Company will not cancel its common stock from trading on AIM if the Board determines that remaining admitted to trading on AIM is in
the best interests of stockholders and warrant holders.


    For further information please contact:
 ReSearch Pharmaceutical Services, Inc.:  +1-215-540-0700
 Daniel M. Perlman, Chairman & Chief
 Executive Officer
 Steven Bell, Chief Financial Officer

 Nominated Adviser and UK Broker:         +44-20-7012-2000
 Arbuthnot Securities Limited
 James Steel/Richard Tulloch


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCEALPPAAXPEFE

Res.Phm.Reg S (LSE:RPSE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Res.Phm.Reg S (LSE:RPSE)
Gráfica de Acción Histórica
De May 2023 a May 2024